|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/21 Rubius Therapeutics, Inc. 10-K 12/31/20 82:12M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.86M
2: EX-21.1 Subsidiaries List HTML 23K
3: EX-23.1 Consent of Expert or Counsel HTML 23K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
14: R1 Document and Entity Information HTML 88K
15: R2 Consolidated Balance Sheets HTML 101K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 40K
17: R4 Consolidated Statements of Operations and HTML 70K
Comprehensive Loss
18: R5 Consolidated Statements of Operations and HTML 26K
Comprehensive Loss (Parenthetical)
19: R6 Consolidated Statements of Convertible Preferred HTML 105K
Stock and Stockholders' Equity (Deficit)
20: R7 Consolidated Statements of Convertible Preferred HTML 25K
Stock and Stockholders' Equity (Deficit)
(Parenthetical)
21: R8 Consolidated Statements of Cash Flows HTML 131K
22: R9 Nature of the Business and Basis of Presentation HTML 32K
23: R10 Summary of Significant Accounting Policies HTML 119K
24: R11 Investments and Fair Value of Financial Assets and HTML 120K
Liabilities
25: R12 Property, Plant and Equipment, Net HTML 64K
26: R13 Debt HTML 52K
27: R14 Convertible Preferred Stock HTML 27K
28: R15 Warrants to Purchase Convertible Preferred Stock HTML 26K
29: R16 Equity HTML 29K
30: R17 Stock-Based Compensation HTML 139K
31: R18 Income Taxes HTML 94K
32: R19 Commitments and Contingencies HTML 30K
33: R20 Leases HTML 81K
34: R21 Net Loss Per Share HTML 56K
35: R22 Related Parties HTML 29K
36: R23 Selected Quarterly Financial Data (Unaudited) HTML 79K
37: R24 Summary of Significant Accounting Policies HTML 170K
(Policies)
38: R25 Summary of Significant Accounting Policies HTML 87K
(Tables)
39: R26 Investments and Fair Value of Financial Assets and HTML 121K
Liabilities (Tables)
40: R27 Property, Plant and Equipment, Net (Tables) HTML 47K
41: R28 Accrued Expenses and Other Current Liabilities HTML 38K
(Tables)
42: R29 Debt (Tables) HTML 49K
43: R30 Stock-Based Compensation (Tables) HTML 130K
44: R31 Income Taxes (Tables) HTML 91K
45: R32 Leases (Tables) HTML 76K
46: R33 Net Loss Per Share (Tables) HTML 57K
47: R34 Selected Quarterly Financial Data (Unaudited) HTML 79K
(Tables)
48: R35 Nature of the Business and Basis of Presentation HTML 58K
(Details)
49: R36 Summary of Significant Accounting Policies HTML 39K
(Details)
50: R37 Summary of Significant Accounting Policies - HTML 37K
Estimated useful life (Details)
51: R38 Summary of Significant Accounting Policies - HTML 113K
Recently Adopted Accounting Pronouncements
(Details)
52: R39 Investments and Fair Value of Financial Assets and HTML 73K
Liabilities (Details)
53: R40 Property, Plant and Equipment, Net (Details) HTML 65K
54: R41 Accrued Expenses and Other Current Liabilities HTML 36K
(Details)
55: R42 Debt (Details) HTML 82K
56: R43 Debt - Current and Non current (Details) HTML 35K
57: R44 Convertible Preferred Stock (Details) HTML 56K
58: R45 Warrants to Purchase Convertible Preferred Stock HTML 45K
(Details)
59: R46 Equity (Details) HTML 62K
60: R47 Stock-Based Compensation (Details) HTML 55K
61: R48 Stock-Based Compensation - Employees, directors HTML 31K
and non-employees (Details)
62: R49 Stock-Based Compensation - Option activity HTML 85K
(Details)
63: R50 Stock-Based Compensation - Performance based stock HTML 84K
options (Details)
64: R51 Stock-Based Compensation - Restricted Common Stock HTML 87K
(Details)
65: R52 Stock-Based Compensation - Compensation expense HTML 64K
(Details)
66: R53 Income Taxes (Details) HTML 48K
67: R54 Income Taxes - U S federal statutory income tax HTML 42K
rate (Details)
68: R55 Income Taxes - Net deferred tax assets (Details) HTML 53K
69: R56 Income Taxes - Valuation allowance for deferred HTML 27K
tax assets (Details)
70: R57 Commitments and Contingencies - Collaborative HTML 31K
Arrangements and Non-collaborative Arrangement
(Details)
71: R58 Commitments and Contingencies - Defined HTML 31K
Contribution Plan (Details)
72: R59 Leases (Details) HTML 57K
73: R60 Leases - Minimum lease payments (Details) HTML 42K
74: R61 Leases - Lease Portfolio (Details) HTML 47K
75: R62 Net Loss Per Share - Weighted Average Shares HTML 39K
(Details)
76: R63 Net Loss Per Share - Antidilutive Securities HTML 35K
(Details)
77: R64 Related Parties (Details) HTML 66K
78: R65 Selected Quarterly Financial Data (Unaudited) HTML 41K
(Details)
80: XML IDEA XML File -- Filing Summary XML 150K
13: XML XBRL Instance -- ruby-20201231x10k_htm XML 2.26M
79: EXCEL IDEA Workbook of Financial Reports XLSX 114K
9: EX-101.CAL XBRL Calculations -- ruby-20201231_cal XML 175K
10: EX-101.DEF XBRL Definitions -- ruby-20201231_def XML 641K
11: EX-101.LAB XBRL Labels -- ruby-20201231_lab XML 1.50M
12: EX-101.PRE XBRL Presentations -- ruby-20201231_pre XML 1.12M
8: EX-101.SCH XBRL Schema -- ruby-20201231 XSD 179K
81: JSON XBRL Instance as JSON Data -- MetaLinks 398± 605K
82: ZIP XBRL Zipped Folder -- 0001558370-21-001412-xbrl Zip 937K
CERTIFICATION PURSUANT TO RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION
I, Jose Carmona, certify that:
1. I have reviewed this Annual Report on Form 10-K of Rubius Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 23, 2021 |
| By: | /s/ Jose Carmona |
|
|
| |
|
|
| Chief Financial Officer |
| | | (Principal Financial Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/23/21 | 8-K | ||
| For Period end: | 12/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/18/21 Rubius Therapeutics, Inc. 8-K:1,9 3/16/21 12:582K Toppan Merrill/FA 3/18/21 Rubius Therapeutics, Inc. 424B5 1:772K Toppan Merrill/FA 3/15/21 Rubius Therapeutics, Inc. 424B5 1:774K Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/28/20 Rubius Therapeutics, Inc. 8-K:5,9 9/23/20 12:359K Toppan Merrill/FA 8/10/20 Rubius Therapeutics, Inc. 10-Q 6/30/20 53:5.3M Toppan Merrill Bridge/FA 5/11/20 Rubius Therapeutics, Inc. 10-Q 3/31/20 53:5M Toppan Merrill Bridge/FA 3/12/20 Rubius Therapeutics, Inc. 10-K 12/31/19 86:13M Toppan Merrill Bridge/FA 11/14/19 Rubius Therapeutics, Inc. 10-Q 9/30/19 67:7.4M Toppan Merrill Bridge/FA 8/01/19 Rubius Therapeutics, Inc. S-3 7:1.7M Toppan Merrill-FA 5/15/19 Rubius Therapeutics, Inc. 10-K/A 12/31/18 5:313K Toppan Merrill Bridge/FA 7/23/18 Rubius Therapeutics, Inc. 8-K:5,8,9 7/17/18 3:223K Toppan Merrill/FA 7/09/18 Rubius Therapeutics, Inc. S-1/A 10:5.6M Toppan Merrill-FA 7/02/18 Rubius Therapeutics, Inc. S-1/A 7:1M Toppan Merrill-FA 6/22/18 Rubius Therapeutics, Inc. S-1 18:11M Toppan Merrill-FA |